These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
210 related articles for article (PubMed ID: 9459155)
61. Serum immunoreactive and bioactive lactogenic hormones in advanced breast cancer patients treated with bromocriptine and octreotide. Anderson E; Ferguson JE; Morten H; Shalet SM; Robinson EL; Howell A Eur J Cancer; 1993; 29A(2):209-17. PubMed ID: 8422285 [TBL] [Abstract][Full Text] [Related]
62. Different survival determinants of metastatic breast cancer patients treated with endocrine therapy or chemo-endocrine therapy. Nomura Y Int J Oncol; 1998 Apr; 12(4):817-24. PubMed ID: 9499441 [TBL] [Abstract][Full Text] [Related]
63. Low dose octreotide and tamoxifen in the treatment of adenocarcinoma of the pancreas. Rosenberg L; Barkun AN; Denis MH; Pollak M Cancer; 1995 Jan; 75(1):23-8. PubMed ID: 7804972 [TBL] [Abstract][Full Text] [Related]
64. Potential role for somatostatin analogues in breast cancer: rationale and description of an ongoing trial. Pollak M; Gallant K; Poisson R; Harris A Metabolism; 1992 Sep; 41(9 Suppl 2):119-20. PubMed ID: 1355585 [TBL] [Abstract][Full Text] [Related]
65. Treatment of patients with metastatic pancreatic and gastrointestinal tumours with the somatostatin analogue Sandostatin: a phase II study including endocrine effects. Klijn JG; Hoff AM; Planting AS; Verweij J; Kok T; Lamberts SW; Portengen H; Foekens JA Br J Cancer; 1990 Oct; 62(4):627-30. PubMed ID: 1977468 [TBL] [Abstract][Full Text] [Related]
66. Treatment of metastatic breast cancer with somatostatin analogues--a meta-analysis. Dolan JT; Miltenburg DM; Granchi TS; Miller CC; Brunicardi FC Ann Surg Oncol; 2001 Apr; 8(3):227-33. PubMed ID: 11314939 [TBL] [Abstract][Full Text] [Related]
67. The effect of danazol on tumour control and weight loss in patients on tamoxifen therapy for advanced breast cancer: a randomised double-blind placebo controlled trial. Bishop JF; Smith JG; Jeal PN; Murray R; Drummond RM; Pitt P; Olver IN; Bhowal AK Eur J Cancer; 1993; 29A(6):814-8. PubMed ID: 8484970 [TBL] [Abstract][Full Text] [Related]
68. Anti-oestrogens in the treatment of breast and gynaecological cancers. Furr BJ Baillieres Clin Obstet Gynaecol; 1988 Sep; 2(3):567-80. PubMed ID: 3069263 [TBL] [Abstract][Full Text] [Related]
69. Systemic therapy of metastatic breast cancer. Rose C Acta Oncol; 1990; 29(3):361-5. PubMed ID: 2363947 [TBL] [Abstract][Full Text] [Related]
70. Chemoprevention of breast cancer. Powles TJ; Hardy JR; Ashley SE; Cosgrove D; Davey JB; Dowsett M; McKinna A; Nash AG; Rundle SK; Sinnett HD Breast Cancer Res Treat; 1989 Oct; 14(1):23-31. PubMed ID: 2690969 [TBL] [Abstract][Full Text] [Related]
71. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients. Lissoni P; Paolorossi F; Tancini G; Ardizzoia A; Barni S; Brivio F; Maestroni GJ; Chilelli M Br J Cancer; 1996 Nov; 74(9):1466-8. PubMed ID: 8912546 [TBL] [Abstract][Full Text] [Related]
72. Breast cancer chemoprevention: studies with 4-HPR alone and in combination with tamoxifen using circulating growth factors as potential surrogate endpoints. Decensi A; Formelli F; Torrisi R; Costa A J Cell Biochem Suppl; 1993; 17G():226-33. PubMed ID: 8007703 [TBL] [Abstract][Full Text] [Related]
73. Towards a molecular basis for tamoxifen resistance in breast cancer. Johnston SR; Dowsett M; Smith IE Ann Oncol; 1992 Jul; 3(7):503-11. PubMed ID: 1498070 [TBL] [Abstract][Full Text] [Related]
74. Contribution of prednisolone to the primary endocrine treatment of advanced breast cancer. Stewart JF; Rubens RD; King RJ; Minton MJ; Steiner R; Tong D; Winter PJ; Knight RK; Hayward JL Eur J Cancer Clin Oncol; 1982 Dec; 18(12):1307-14. PubMed ID: 6891929 [TBL] [Abstract][Full Text] [Related]
76. The definition of the 'no change' category in patients treated with endocrine therapy and chemotherapy for advanced carcinoma of the breast. Howell A; Mackintosh J; Jones M; Redford J; Wagstaff J; Sellwood RA Eur J Cancer Clin Oncol; 1988 Oct; 24(10):1567-72. PubMed ID: 3208800 [TBL] [Abstract][Full Text] [Related]
77. Tamoxifen plus bromocriptine versus tamoxifen plus placebo in advanced breast cancer: results of a double blind multicentre clinical trial. Bonneterre J; Mauriac L; Weber B; Roche H; Fargeot P; Tubiana-Hulin M; Sevin M; Chollet P; Cappelaere P Eur J Cancer Clin Oncol; 1988 Dec; 24(12):1851-3. PubMed ID: 3065085 [TBL] [Abstract][Full Text] [Related]
78. A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Powles TJ; Hardy JR; Ashley SE; Farrington GM; Cosgrove D; Davey JB; Dowsett M; McKinna JA; Nash AG; Sinnett HD Br J Cancer; 1989 Jul; 60(1):126-31. PubMed ID: 2679843 [TBL] [Abstract][Full Text] [Related]
79. The effect of tamoxifen on plasma growth hormone and prolactin in postmenopausal women with advanced breast cancer. Paterson AG; Turkes A; Groom GV; Webster DJ Eur J Cancer Clin Oncol; 1983 Jul; 19(7):919-22. PubMed ID: 6684048 [TBL] [Abstract][Full Text] [Related]
80. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients. Lissoni P; Ardizzoia A; Barni S; Paolorossi F; Tancini G; Meregalli S; Esposti D; Zubelewicz B; Braczowski R Oncol Rep; 1995 Sep; 2(5):871-3. PubMed ID: 21597833 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]